PSC
KYTH

Piper Sandler & Co’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Piper Sandler & Co’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,000
Closed -$401K – 148
2015
Q1 		$401K Buy
+8,000
New +$336K 0.17% 60

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Piper Sandler & Co's KYTH Position: Q2 2015 in Review

Piper Sandler & Co sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q2 2015, closing a stake of 8,000 shares — an estimated $401K sold.

Piper Sandler & Co first reported a position in KYTH in Q1 2015 and held it in 1 quarter. The position peaked at $401K in Q1 2015. 153 funds tracked by Wall St. Rank hold KYTH as of Q2 2015.

  • Piper Sandler & Co reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 8,000 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q2 2015, an estimated $401K.
  • Piper Sandler & Co first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q1 2015 and held it in 1 quarter.
  • Piper Sandler & Co's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $401K in Q1 2015.
  • 153 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.